Works by Date, Koji


Results: 11
    1

    Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer.

    Published in:
    JAMA Network Open, 2023, v. 6, n. 7, p. e2322915, doi. 10.1001/jamanetworkopen.2023.22915
    By:
    • Kawachi, Hayato;
    • Yamada, Tadaaki;
    • Tamiya, Motohiro;
    • Negi, Yoshiki;
    • Goto, Yasuhiro;
    • Nakao, Akira;
    • Shiotsu, Shinsuke;
    • Tanimura, Keiko;
    • Takeda, Takayuki;
    • Okada, Asuka;
    • Harada, Taishi;
    • Date, Koji;
    • Chihara, Yusuke;
    • Hasegawa, Isao;
    • Tamiya, Nobuyo;
    • Ishida, Masaki;
    • Katayama, Yuki;
    • Morimoto, Kenji;
    • Iwasaku, Masahiro;
    • Tokuda, Shinsaku
    Publication type:
    Article
    2

    Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study.

    Published in:
    Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1399889
    By:
    • Naoya Nishioka;
    • Hayato Kawachi;
    • Tadaaki Yamada;
    • Motohiro Tamiya;
    • Yoshiki Negi;
    • Yasuhiro Goto;
    • Akira Nakao;
    • Shinsuke Shiotsu;
    • Keiko Tanimura;
    • Takayuki Takeda;
    • Asuka Okada;
    • Taishi Harada;
    • Koji Date;
    • Yusuke Chihara;
    • Isao Hasegawa;
    • Nobuyo Tamiya;
    • Taiki Masui;
    • Natsuki Sai;
    • Masaki Ishida;
    • Yuki Katayama
    Publication type:
    Article
    3

    Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%.

    Published in:
    Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1348034
    By:
    • Shota Takei;
    • Hayato Kawachi;
    • Tadaaki Yamada;
    • Motohiro Tamiya;
    • Yoshiki Negi;
    • Yasuhiro Goto;
    • Akira Nakao;
    • Shinsuke Shiotsu;
    • Keiko Tanimura;
    • Takayuki Takeda;
    • Asuka Okada;
    • Taishi Harada;
    • Koji Date;
    • Yusuke Chihara;
    • Isao Hasegawa;
    • Nobuyo Tamiya;
    • Yuki Katayama;
    • Naoya Nishioka;
    • Kenji Morimoto;
    • Masahiro Iwasaku
    Publication type:
    Article
    4

    Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.

    Published in:
    Oncologist, 2022, v. 27, n. 11, p. 903, doi. 10.1093/oncolo/oyac193
    By:
    • Chihara, Yusuke;
    • Takeda, Takayuki;
    • Goto, Yasuhiro;
    • Nakamura, Yoichi;
    • Tsuchiya-Kawano, Yuko;
    • Nakao, Akira;
    • Onoi, Keisuke;
    • Hibino, Makoto;
    • Fukuda, Minoru;
    • Honda, Ryoichi;
    • Yamada, Takahiro;
    • Taniguchi, Ryusuke;
    • Sakamoto, Sinjiro;
    • Date, Koji;
    • Nagashima, Seiji;
    • Tanzawa, Shigeru;
    • Minato, Koichi;
    • Nakatani, Koichi;
    • Izumi, Miiru;
    • Shimose, Takayuki
    Publication type:
    Article
    5
    6
    7

    Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.

    Published in:
    Investigational New Drugs, 2024, v. 42, n. 5, p. 538, doi. 10.1007/s10637-024-01467-7
    By:
    • Tachibana, Yusuke;
    • Morimoto, Kenji;
    • Yamada, Tadaaki;
    • Kawachi, Hayato;
    • Tamiya, Motohiro;
    • Negi, Yoshiki;
    • Goto, Yasuhiro;
    • Nakao, Akira;
    • Shiotsu, Shinsuke;
    • Tanimura, Keiko;
    • Takeda, Takayuki;
    • Okada, Asuka;
    • Harada, Taishi;
    • Date, Koji;
    • Chihara, Yusuke;
    • Hasegawa, Isao;
    • Tamiya, Nobuyo;
    • Katayama, Yuki;
    • Nishioka, Naoya;
    • Iwasaku, Masahiro
    Publication type:
    Article
    8
    9

    Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy.

    Published in:
    Drugs & Aging, 2023, v. 40, n. 6, p. 563, doi. 10.1007/s40266-023-01034-4
    By:
    • Morimoto, Kenji;
    • Yamada, Tadaaki;
    • Takeda, Takayuki;
    • Shiotsu, Shinsuke;
    • Date, Koji;
    • Harada, Taishi;
    • Tamiya, Nobuyo;
    • Chihara, Yusuke;
    • Takemura, Yoshizumi;
    • Yamada, Takahiro;
    • Kanda, Hibiki;
    • Ishida, Masaki;
    • Yoshimura, Akihiro;
    • Iwasaku, Masahiro;
    • Tokuda, Shinsaku;
    • Kim, Young Hak;
    • Takayama, Koichi
    Publication type:
    Article
    10

    Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.

    Published in:
    Targeted Oncology, 2023, v. 18, n. 6, p. 915, doi. 10.1007/s11523-023-01012-1
    By:
    • Morimoto, Kenji;
    • Yamada, Tadaaki;
    • Kawachi, Hayato;
    • Tamiya, Motohiro;
    • Negi, Yoshiki;
    • Goto, Yasuhiro;
    • Nakao, Akira;
    • Shiotsu, Shinsuke;
    • Tanimura, Keiko;
    • Takeda, Takayuki;
    • Okada, Asuka;
    • Harada, Taishi;
    • Date, Koji;
    • Chihara, Yusuke;
    • Hasegawa, Isao;
    • Tamiya, Nobuyo;
    • Nishioka, Naoya;
    • Katayama, Yuki;
    • Iwasaku, Masahiro;
    • Tokuda, Shinsaku
    Publication type:
    Article
    11